Doctiplus - We are allways here!
Diabetes (Type 2)
Weekly Report
- 20 new clinical trials registered across 10 countries.
- 1,974 trials actively recruiting patients worldwide.
- Notable trial: A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardio... (3000 patients).
- 2,218 new research papers published.
- Top cited: "Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes acro..." (Nature Communications, 33 citations).
- Drug safety: Most reported effect across tracked medications (metformin, semaglutide, sitagliptin, empagliflozin, insulin glargine) was Off Label Use.
- No active drug recalls for tracked medications this week.
The week in numbers
Trials by country
Trials by phase
New clinical trials registered this week for Diabetes (Type 2). Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.
This week's new registrations
20 trials registered for Diabetes (Type 2). Each links to its full record on ClinicalTrials.gov.
| # | Trial ↓ | Phase ↕ | Status ↕ | Enrollment ↕ | Country ↕ |
|---|---|---|---|---|---|
| 01 | A Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and Participants With Type 2 Diabetes Diabetes (Type 2) · Novo Nordisk A/S (NCT07896109) | Phase 1 | Not Yet Recruiting | 121 | Germany |
| 02 | A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk Diabetes (Type 2) · Eli Lilly and Company (NCT07900633) | Phase 3 | Not Yet Recruiting | 3,000 | United States |
| 03 | A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease Diabetes (Type 2) · Beijing University of Chinese Medicine (NCT07907965) | Phase 2 | Active Not Recruiting | 15 | China |
| 04 | Information-Based Interventions for Influenza Vaccination Among Older Adults With Diabetes in Yangzhou, China Diabetes (Type 2) · Southeast University, China (NCT07901673) | Other | Completed | 759 | China |
| 05 | Plantar Load Analysis of Neuropathic and Neuroischaemic Diabetes-Related Foot Ulceration Diabetes (Type 2) · The Leeds Teaching Hospitals NHS Trust (NCT07901478) | Other | Completed | 16 | United Kingdom |
| 06 | Comparison of Negative Pressure Wound Therapy Versus Moist Wound Dressing in Diabetic Foot Ulcer Patients Diabetes (Type 2) · Abbas Institute of Medical Sciences (NCT07898202) | Other | Not Yet Recruiting | 60 | Pakistan |
| 07 | Care COMPASS Study Diabetes (Type 2) · Fitbit LLC (NCT07904793) | Other | Not Yet Recruiting | 200 | United States |
| 08 | Comparative Effects of tDCS and tACS on Pain, Dexterity, and Strength in Diabetic Peripheral Neuropathy Diabetes (Type 2) · University of Management and Technology Lahore (NCT07905729) | Other | Active Not Recruiting | 46 | Pakistan |
| 09 | Different Aerobic-to-Resistance Training Ratios in Adults Aged 50 Years and Older With Prediabetes Diabetes (Type 2) · China Institute of Sport Science (NCT07904962) | Other | Not Yet Recruiting | 212 | China |
| 10 | Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes Diabetes (Type 2) · Regeneron Pharmaceuticals (NCT07896265) | Phase 3 | Not Yet Recruiting | 3,000 | N/A |
| 11 | Adding Acetazolamide on Top of SGLT2 Inhibition in Persons With Type 2 Diabetes Diabetes (Type 2) · University Health Network, Toronto (NCT07902726) | Phase 2 | Not Yet Recruiting | 20 | Canada |
| 12 | A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China Diabetes (Type 2) · Novo Nordisk A/S (NCT07900438) | Phase 4 | Recruiting | 300 | China |
| 13 | Evaluation of MTHFR and DNMT3B Gene Polymorphisms Along With Periodontal Clinical Parameters in Healthy Individuals and Individuals With Type 2 Diabetes and Periodontitis Diabetes (Type 2) · Akdeniz University (NCT07905209) | Other | Active Not Recruiting | 200 | Turkey (Türkiye) |
| 14 | Physiologic Insulin Resensitization (PIR) Treatment in Patients With a Diagnosis of Type 2 Diabetes Mellitus (T2DM) Diabetes (Type 2) · University of Alabama at Birmingham (NCT07906470) | Other | Not Yet Recruiting | 60 | United States |
| 15 | Efficacy of the pA1c®HI Postbiotic in Metabolic Regulation in Healthy Individuals With Hyperglycemia Diabetes (Type 2) · Genbioma Aplicaciones SL (NCT07903870) | Phase 1 | Not Yet Recruiting | 100 | Spain |
| 16 | A Case-Control Study Revealing Intraocular Microenvironment Characteristics in Patients With Ocular Diseases Based on Multi-Omics Analysis Diabetes (Type 2) · First Affiliated Hospital of Zhejiang University (NCT07897513) | Other | Not Yet Recruiting | 150 | N/A |
| 17 | Acupuncture Plus Mecobalamin for Diabetic Cardiac Autonomic Neuropathy Diabetes (Type 2) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (NCT07907536) | Other | Recruiting | 60 | China |
| 18 | Better Care Closer to Home: Enhancing Primary and Community Care Diabetes (Type 2) · Universidad Complutense de Madrid (NCT07905664) | Other | Not Yet Recruiting | 84 | Canada |
| 19 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes Diabetes (Type 2) · Paulex Bio Inc. (NCT07901595) | Phase 2 | Not Yet Recruiting | 147 | N/A |
| 20 | Sarcopenia Risk in Obese T2DM Patients Diabetes (Type 2) · Bandırma Onyedi Eylül University (NCT07905274) | Other | Not Yet Recruiting | 150 | Turkey (Türkiye) |
Adverse event reports
Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Diabetes (Type 2). These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.
Reports by drug
| Drug | Top effect | Count |
|---|---|---|
| metformin | Diarrhoea | 2,240 |
| semaglutide | Nausea | 2,963 |
| sitagliptin | Nausea | 330 |
| empagliflozin | Nausea | 823 |
| insulin glargine | Off Label Use | 4,775 |
Recalls & safety notices
FDA drug recall notices for medications related to Diabetes (Type 2). If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.
No active drug recalls for tracked medications this period.
Published research
Recently published peer-reviewed studies related to Diabetes (Type 2), sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.
| # | Study | Journal | Date | Source |
|---|---|---|---|---|
| 01 |
Serum sclerostin in relation to insulin resistance and epicardial fat thickness in obese women.
View abstractOBJECTIVES: Visceral obesity is closely linked to insulin resistance and cardiometabolic risk. Epicardial adipose tissue, commonly assessed by epicardial fat thickness (EFT), is a clinically relevant fat depot associated with early cardiac remodelling. Sclerostin, a bone-derived protein, may play a role in crosstalk between the skeleton and adipose tissue. However, its relationship with insulin resistance and cardiac visceral fat remains unclear. This study aimed to evaluate serum sclerostin levels and their association with insulin resistance and EFT in obese women. METHODS: This case-control study included 90 women (55 obese and 35 age-matched controls). Participants underwent anthropometric and metabolic assessment, including serum sclerostin measurement. Insulin resistance was evaluated using HOMA-IR, and EFT was assessed by echocardiography. Correlation, ROC, and regression analyses were performed. RESULTS: Serum sclerostin levels were significantly higher in obese women than in controls (p<0.001). Sclerostin was positively correlated with fasting insulin, HOMA-IR, triglycerides, and EFT. Levels were higher in insulin-resistant obese participants than in metabolically healthier obese individuals. ROC analysis showed good discriminative ability for insulin resistance (AUC=0.89) and moderate accuracy for identifying increased EFT (AUC=0.80). In multivariate analysis, BMI, but not sclerostin, remained an independent predictor of increased EFT. CONCLUSIONS: Serum sclerostin is elevated in obese women and is associated with insulin resistance and adverse metabolic profiles. Although not independently associated with epicardial fat thickness, it reflects metabolic dysfunction related to visceral adiposity and may serve as an indicator of metabolically unhealthy obesity within this cohort. |
Hormone molecular biology and clinical investigation | 2026 Nov 2 | PubMed |
| 02 |
Health and Genomic Literacy Among Individuals at Risk for Type 2 Diabetes: A Feasibility Pilot Study.
View abstractHealth literacy requires new competences as healthcare evolves, particularly when genomics is applied to disease prevention. Genomic literacy has been described from the same foundations as health literacy, but it also has its own unique characteristics, including an emphasis on numeracy. The aim of this longitudinal feasibility pilot study was to assess the health and genomic literacy of participants at risk of Type 2 diabetes, to better understand the factors influencing health and genomic literacy, as well as the relationship between these two literacy perspectives. The Everyday Health Information Literacy (EHIL) instrument, the European Health Literacy Survey Questionnaire (HLS-EU-Q16), and genomic literacy measures were used with 60 participants at baseline, and 49 participants completed postsurveys. Participants were informed of their personal polygenic risk score (PRS) for Type 2 diabetes before they filled the postsurveys. The data were analyzed using statistical methods. Health literacy did not change significantly during intervention, but genomic literacy, Section A, scores improved at postsurvey. There was no association between health literacy, EHIL, and genomic literacy, Section A, at baseline; however, a correlation was observed at postsurvey. Motivation was also correlated with health literacy, HLS-EU-Q16, and genomic literacy, Sections A and C, at postsurvey. In contrast, education, which appeared to influence genomic literacy, Section A, at baseline, no longer had a significant role at postsurvey. Even brief health counseling and genomic risk information can improve genomic literacy. We recommend that PRS results be disclosed in person, combined with lifestyle counseling. Personal counseling allows for the results to be explained according to the participant's health literacy and understanding. |
Nursing research and practice | 2026 | PubMed |
| 03 |
The State of Health in Jordan, 1990-2023: A Systematic Analysis for the Global Burden of Disease Study.
View abstractBACKGROUND: Jordan's health system has evolved amid rapid urbanization and the strain of hosting one of the world's largest refugee populations per capita. This study comprehensively evaluates national disease burden trends in Jordan from 1990 to 2023 to inform health priorities. METHODS: Using the Global Burden of Disease (GBD) 2023 framework, we analyzed age-standardized rates of disability-adjusted life years (DALYs), years lived with disability (YLDs), and years of life lost (YLLs) across 370 diseases and 88 risk factors. Data were derived from national censuses, health surveys, disease registries, and hospital records, and harmonized using standardized GBD modeling and estimation procedures. Analyses were stratified by age, sex, and cause. RESULTS: Between 1990 and 2023, age-standardized DALYs declined by 33.88% (95% UI: -37.38 to -30.59), with greater reductions in males (-38.83%; -42.22 to -35.60) than females (-27.22%; -31.33 to -23.58). YLLs decreased by 49.38% (-50.93 to -47.68), while YLDs remained comparatively stable (2.49%; -2.37 to 7.47). Using mutually exclusive GBD Level 3 causes, ischemic heart disease and diabetes mellitus were the two leading causes of DALYs in 2023. Diabetes mellitus rose from 7th place in 1990 to 2nd place in 2023, while neonatal disorders declined from 1st to 7th place. Metabolic risks remained important contributors to the overall disease burden. Jordan's age-standardized diabetes DALY rate in 2023 was approximately 1.56 times the global rate. CONCLUSION: Jordan's health profile has shifted toward a greater burden from noncommunicable diseases, while age-standardized health loss and premature mortality have declined substantially. In contrast, nonfatal disability changed comparatively little. These findings provide an evidence base for primary prevention of NCDs and for long-term strategies addressing the country's evolving health challenges. |
Health science reports | 2026 Nov | PubMed |
| 04 |
Global Landscape of Telehealth Interventions for Type 2 Diabetes Self-Care: A Scoping Review of Nursing Roles, Care Models, and Outcomes.
View abstractBACKGROUND: Type 2 diabetes mellitus (T2DM) requires ongoing self-care support to minimize preventable complications. Telehealth interventions have the potential to extend diabetes self-management education and support beyond conventional face-to-face care. However, the specific contributions of nursing roles, conceptual frameworks, and digital care architectures have not been comprehensively synthesized. OBJECTIVE: This scoping review aimed to map global evidence on telehealth interventions for T2DM self-care. METHODS: The review was conducted in accordance with Arksey and O'Malley's framework, JBI scoping review guidance, and the PRISMA Extension for Scoping Reviews. Electronic databases including PubMed/MEDLINE, EBSCOhost, Scopus, Taylor AND Francis Online, ScienceDirect, and Sage Journals, were systematically searched for empirical studies published between January 1, 2021, to June 26, 2026, examining telehealth, mHealth, telenursing, or digital self-care interventions for adults with T2DM involving nursing or nursing-relevant digital care component. Data were charted using the systematic table and synthesized through descriptive and thematic analysis. RESULTS: A total of 26 studies were included, representing diverse models such as app-based self-management, messaging platforms, telemonitoring, virtual education, EHR-supported discharge pathways, virtual group visits, and comprehensive telehealth. Nursing roles were categorized as digital education, clinical monitoring, care coordination, behavioral coaching, medication and follow-through support, peer-support moderation, and digital onboarding. Of the 26 included studies, nine (34.6%) were classified as nurse-led, five (19.2%) as nurse-supported, seven (26.9%) as multidisciplinary/team-based, and five (19.2%) had insufficient reporting to isolate a nurse-specific intervention role. Interventions featuring structured nurse involvement, individualized feedback, theory-informed behavior-change strategies, and escalation pathways demonstrated the most consistent improvements in self-care behaviors and selected glycemic outcomes, particularly HbA1c and fasting blood glucose. CONCLUSION: Telehealth interventions for T2DM self-care should be regarded as hybrid care models rather than solely technology-based tools. The synthesized evidence supports nurse-mediated, theory-informed, and equity-sensitive digital diabetes care, while underscoring the need for improved reporting on nursing scope, digital engagement, clinical escalation, fidelity, cost, and implementation context. |
Patient preference and adherence | 2026 | PubMed |
| 05 |
The relationship between homocysteine levels and idiopathic acute peripheral facial palsy in adult patients.
View abstractOBJECTIVE: This study aimed to evaluate changes in serum homocysteine (Hcy) levels during the acute phase and recovery period in adult patients with idiopathic peripheral facial palsy (IPFP) and to explore whether Hcy is associated with the presence, severity, and short-term clinical course of IPFP. Given the established relationship of Hcy with endothelial dysfunction, oxidative stress, and microvascular injury, we hypothesized that Hcy levels would be elevated during the acute phase of IPFP and would change during recovery. MATERIALS AND METHODS: In this prospective, hypothesis-driven exploratory case-control study conducted between December 2023 and December 2024, 80 adult patients with IPFP and 80 demographically matched healthy controls were included. Serum vitamin B12, folic acid, and Hcy levels were measured in all participants. Patients were followed for 8 weeks with serial House-Brackmann Scale evaluations, and Hcy levels were re-measured at the first month. Potential confounders, including demographic variables, comorbidities, vitamin B12, folic acid, and metabolic factors, were considered in the analysis. RESULTS: Folic acid levels were significantly lower and Hcy levels were significantly higher in the patient group than in the control group at baseline. First-month Hcy levels decreased significantly and did not differ from control levels; however, this reduction may have been partly influenced by vitamin B1, B6, B12, and folic acid supplementation administered to half of the patients. In the multivariate logistic regression model, Hcy levels and diabetes mellitus were independently associated with the presence of IPFP. However, Hcy levels were not associated with initial House-Brackmann Scale grade, recovery time, or eighth-week clinical outcomes. At the eighth-week evaluation, 80.0% of patients were classified as HBS Grades I-II and 91.3% as Grades I-III. CONCLUSION: Serum Hcy levels were elevated during the acute phase of IPFP and decreased toward control levels at the first-month follow-up; however, this reduction cannot be attributed solely to clinical recovery, as vitamin supplementation in half of the patients may have contributed to the decrease in Hcy levels. These findings suggest that Hcy may represent a transient metabolic, inflammatory, or microvascular biomarker associated with the acute disease state rather than a causal determinant of disease severity or short-term prognosis. Given the observational design of the study and the potential influence of folate status, diabetes mellitus, and other metabolic or lifestyle-related factors, causality cannot be inferred. Larger prospective studies are needed to clarify whether Hcy has a mechanistic role in IPFP or primarily reflects acute inflammatory-metabolic stress. |
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery | 2026 Oct 31 | PubMed |
| 06 |
Alkaline phosphatase refines FIB-4-based prediction of liver outcomes and mortality in MASLD.
View abstractBACKGROUND: FIB-4 is recommended for first-line MASLD risk stratification but excludes cholestatic liver enzymes. AIMS: To assess whether alkaline phosphatase (ALK) improves prediction of major adverse liver outcomes (MALO) and mortality beyond FIB-4. METHODS: In this retrospective cohort study (2004-2025), adults aged ≥35 years with MASLD or type 2 diabetes with BMI >27 kg/m² were classified by baseline ALK ≥120 U/L and age-adjusted FIB-4 strata. Cause-specific Cox models assessed 10-year MALO and mortality. RESULTS: Among 388,933 participants (mean age 59 years; 53% female), 35,073 (9%) had elevated ALK. Ten-year MALO incidence was higher with elevated ALK across low (1.5%vs 1.1%), intermediate (2.8%vs 1.6%), and high FIB-4 strata (11.9%vs 4.5%). Compared with low FIB-4 and normal ALK, adjusted hazard ratios for MALO were 1.41 (95% CI 1.25-1.59), 2.58 (2.17-3.07), and 9.57 (8.06-11.3) for low, intermediate, and high FIB-4 with elevated ALK, respectively. FIB-4 and ALK were independently associated with MALO, with significant interaction (P < 0.001) and improved event reclassification. Findings were consistent after incorporating GGT. CONCLUSIONS: Elevated ALK identifies MASLD patients at higher liver-related risk and modifies FIB-4-associated risk. Incorporating cholestatic enzyme status into FIB-4-based assessment may improve non-invasive triage and referral decisions. |
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2026 Oct 31 | PubMed |
| 07 | Sex Hormones and CKD Progression in Type 2 Diabetes: Look AHEAD Sex Hormone Study. | American journal of kidney diseases : the official journal of the National Kidney Foundation | 2026 Oct 31 | PubMed |
| 08 | Obesity Paradox and Non-Arteritic Anterior Ischemic Optic Neuropathy Risk. | Ophthalmology | 2026 Oct 31 | PubMed |
| 09 |
Swimming exercise protects against diabetic cardiomyopathy through suppression of FABP4-associated CTRP3 degradation.
View abstractBACKGROUND: Diabetic cardiomyopathy (DCM) is a major cardiovascular complication of type 2 diabetes mellitus (T2D) characterized by metabolic dysregulation, oxidative stress, chronic inflammation, and progressive cardiac dysfunction. Although swimming exercise has been recognized as an effective non-pharmacological intervention for DCM, the molecular mechanisms underlying its cardioprotective effects remain poorly understood. This study aimed to identify the key exercise-responsive molecular targets involved in DCM and elucidate the mechanisms by which swimming exercise attenuates diabetic cardiac injury. METHODS: Bioinformatic analyses were performed using public transcriptomic datasets to identify hub genes associated with swimming exercise-mediated protection against DCM. A streptozotocin/high-fat diet-induced T2D mouse model was established and subjected to low- or high-intensity swimming exercise interventions. Cardiac function, histopathology, metabolic parameters, oxidative stress markers, and inflammatory cytokines were evaluated. Gain-of-function experiments using AAV9-mediated cardiac fatty acid-binding protein 4 (FABP4) overexpression and C1q/TNF-related protein 3 (CTRP3) mutant constructs were conducted in vivo and in vitro. Protein-protein interactions were investigated using co-immunoprecipitation, molecular docking, thermal shift assays, and ubiquitination analyses. RESULTS: Bioinformatic screening identified FABP4 as the top-ranked exercise-responsive hub gene associated with metabolic pathways in DCM. Swimming exercise dose-dependently improved glucose homeostasis, insulin sensitivity, oxidative balance, systemic inflammation, and anxiety-like behaviors in diabetic mice. Concurrently, swimming exercise markedly alleviated myocardial fibrosis, cardiac dysfunction, and myocardial injury while suppressing cardiac FABP4 expression. FABP4 overexpression markedly attenuated the favorable cardiac and metabolic phenotypes observed in swimming-trained diabetic mice, resulting in impaired mitochondrial respiration and glycolysis, enhanced oxidative stress, exaggerated inflammatory responses, and aggravated cardiac remodeling. In vitro, FABP4 interacted with CTRP3 and promoted CTRP3 ubiquitination-associated proteasomal degradation. AICAR treatment weakened the FABP4-CTRP3 interaction and preserved CTRP3 protein stability in vitro. Furthermore, N63 of CTRP3 was identified as an important residue contributing to FABP4 interaction and CTRP3 protein stability. The N63A mutation reduced CTRP3 stability and attenuated AICAR-associated metabolic, antioxidative, and anti-inflammatory protection in vitro, while in vivo expression of CTRP3-N63A was associated with impaired cardiac protection during swimming intervention. CONCLUSIONS: These findings identify FABP4 as an exercise-responsive regulator associated with diabetic cardiac injury and reveal a potential FABP4-CTRP3 protein-stability mechanism supported by cellular experiments and CTRP3 functional manipulation. Swimming exercise attenuates the development of diabetes-associated cardiac dysfunction and remodeling by suppressing FABP4, whereas the cellular mechanistic findings suggest that regulation of the FABP4-CTRP3 protein-stability axis may contribute to these cardioprotective effects. However, whether swimming exercise directly regulates endogenous myocardial CTRP3 stability in vivo remains to be established. |
Cellular signalling | 2026 Oct 31 | PubMed |
| 10 |
Patient-held tools supporting gestational diabetes mellitus (GDM) care across the perinatal continuum: a scoping review.
View abstractGestational diabetes mellitus (GDM) requires continuous care across the perinatal period, yet fragmented systems create gaps in follow-up and coordination. Patient-held tools support self-management and continuity, but their scope across the perinatal continuum has not been synthesized. We conducted a scoping review following Arksey and O'Malley guidelines, searching five databases (MEDLINE, EMBASE, PsycINFO, CINAHL, Web of Science) from January 2000 to November 2025. Two reviewers independently screened and extracted data on patient-held GDM tools in pregnancy, postpartum, or both. 62 studies from 24 countries were included. Most tools were mobile applications (n = 48, 77%), predominantly targeting the prenatal period (n = 44, 71%). Common features included glucose monitoring, education, and provider communication. Some studies reported improvements in glycemic control, engagement, and satisfaction, though implementation outcomes (n = 48, 77%) were more commonly reported than clinical outcomes (n = 28, 45%). Only 12 unique tools supported prenatal-to-postpartum continuity. Key barriers included health literacy, technological limitations, and health system challenges; facilitators included personalized content, ease of use, and real-time visual feedback. Patient-held tools show promise for short-term outcomes; however, continuity of care remains infrequently reported, possibly reflecting gaps in tool design, reporting, or both. Future tools should address equity barriers and incorporate continuity mechanisms to reduce long-term cardiometabolic risk. |
Diabetes research and clinical practice | 2026 Oct 31 | PubMed |
| 11 |
SGLT2 inhibitor-induced genitourinary infections and the consequent antimicrobial-antidiabetic drug interactions: A narrative review of clinical and pharmacovigilance concern.
View abstractSodium glucose cotransporter 2 (SGLT2) inhibitors provide cardiovascular and renal benefits in type 2 diabetes mellitus, chronic kidney disease, and heart failure, but their use is associated with genitourinary (GU) infections and medication-safety concerns during antimicrobial treatment. This narrative review integrate evidence regarding SGLT2 inhibitor-associated GU infections, antimicrobial-antidiabetic drug interactions, pharmacovigilance, clinical management, and antimicrobial stewardship. Evidence from randomized controlled trials, meta-analysis, observational studies, pharmacokinetic studies and pharmacovigilance databases were used to synthesise on infection risk, drug interactions, management and safety issues in vulnerable populations. To identify relevant evidence narrative review was completed with evidence found in Pubmed, Google scholar, Clinical trial gov between 2020 and 2026. A purposive selection of literature was conducted to identify studies relevant to the article with a methodological strength, and not a systematic search was used.SGLT2 inhibitors demonstrate a more consistent association with genital mycotic infections than urinary tract infections (UTIs). Most GU infections are mild to moderate and can be treated with standard antimicrobial or antifungal therapy without routine discontinuation of SGLT2 inhibitors. SGLT2 inhibitors have low potential for drug-drug interactions, however, exposure to other agents can altered by strong enzyme inducers like rifampin, and this effect varies by SGLT2 inhibitor. Pharmacovigilance complements trial evidence by identifying safety signals, although disproportionality signals require clinical validation. Antimicrobial stewardship also enables treatment, avoidance of unnecessary prophylaxis, evaluation of risk factors, and assessment of concomitant medications and interactions. |
Diabetes research and clinical practice | 2026 Oct 31 | PubMed |
| 12 |
Waist circumference as a simple indicator of visceral obesity in type 2 diabetes.
View abstractINTRODUCTION: Obesity is a common occurrence in individuals diagnosed with type 2 diabetes (T2DM). Typically, the assessment of obesity degree involves the measurement of the visceral fat area (VFA). Nevertheless, evaluating VFA through this method can be costly. Consequently, our study sought to evaluate the effectiveness of physical measurement indexes in precisely measuring VFA, particularly in individuals diagnosed with T2DM. METHODS: In the period between March 2018 and October 2024, a cohort of 5075 patients was gathered at the Metabolic Management Center (MMC) to investigate the correlation between anthropometric indices and VFA. Receiver Operating Characteristic (ROC) curves were generated for various obesity indices, elucidating their effectiveness in discerning patients with and without visceral obesity. RESULTS: Various anthropometric measures, including a body shape index (ABSI), body roundness index (BRI), body mass index (BMI), waist-hip ratio (WHR), waist-height ratio (WHtR), waist circumference (WC), and hip circumference (HC), were analyzed for comparative purposes. Among these, waist circumference (WC) exhibited the highest AUC value in estimating visceral obesity (VFA) for both male (AUC = 0.881, 95% CI: 0.870-0.893) and female (AUC = 0.891, 95% CI: 0.875-0.907). CONCLUSIONS: WC is the best in evaluating visceral obesity in patients with T2DM. |
Diabetes research and clinical practice | 2026 Oct 31 | PubMed |
| 13 |
From dental screening to diabetes care: effectiveness of screening, referral, and integrated care pathways for dysglycaemia in dental settings-a systematic review and meta-analysis.
View abstractDental visits may reach adults with unrecognised dysglycaemia, but clinical value depends on progression from risk identification to medical diagnosis and care. We systematically reviewed dental-setting studies reporting screening, referral, confirmatory assessment or linked-care outcomes. MEDLINE/PubMed, Embase and Web of Science Core Collection were searched from inception through 12 October 2026. Two reviewers independently screened 751 deduplicated records and 71 potentially eligible full texts. Forty-eight unique eligible reports informed the qualitative evidence map15 studies provided referral denominators. Across 2,727 referrals, 1,269 participants completed the reported follow-up milestone. Random-effects pooled completion was 56.0% (95% CI 45.8-65.7% I = 95.1%prediction interval 21.6-85.5%). In seven studies, 217 of 715 diagnostic completers had confirmed prediabetes or diabetes pooled yield was 39.5% (95% CI 26.2-54.5% I = 89.1%). Endpoint definitions and diagnostic criteria differed materially. Integrated pathways were associated with high completion in some observational reports, but comparative evidence was sparse and confounded. Dental screening can identify dysglycaemia however, the highly heterogeneous completion estimate should not be treated as a universal programme effect. Closed-loop referral and related implementation components remain proposed strategies requiring pragmatic comparative evaluation. |
Diabetes research and clinical practice | 2026 Oct 31 | PubMed |
| 14 |
Association of GLP-1 receptor agonist therapy with cardiovascular outcomes in patients with MASLD: A translational study.
View abstractPatients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes (T2D) are at increased risk of adverse cardiovascular outcomes, potentially involving systemic metabolic dysfunction and cardiac remodeling. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve metabolic dysfunction in MASLD; however, their associations with cardiovascular outcomes and effects on MASLD-associated cardiac remodeling remain incompletely understood. In this translational study, we integrated a real-world TriNetX cohort of patients with MASLD and T2D with complementary experimental studies in a mouse model of MASLD. Following propensity score matching, 42,910 patients were included in each treatment group. GLP-1 RA therapy was associated with a lower risk of the primary composite cardiovascular outcome compared with sulfonylurea therapy (hazard ratio 0.87, 95% confidence interval 0.84-0.91; P < 0.001), although this association was not statistically significant in 90-day and 180-day landmark analyses. In Western diet-fed mice, GLP-1 RA treatment improved selected indices of cardiac function and attenuated cardiomyocyte hypertrophy. Although myocardial fibrosis was numerically reduced, the difference compared with vehicle-treated mice was not statistically significant (P = 0.28). Molecular analyses showed reduced expression of fibrosis- and extracellular matrix remodeling-related markers, including CTGF, TGF-β1, and vimentin. Collectively, GLP-1 RA therapy was associated with lower cardiovascular risk in the primary observational analysis, although this finding was not consistently supported by sensitivity analyses. Complementary experimental findings suggest improvements in selected cardiac functional indices and changes in fibrosis-associated molecular remodeling, warranting further investigation. |
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | 2026 Oct 31 | PubMed |
| 15 |
Cross-cultural adaptation and measurement properties of the Spanish Foot Care Confidence Scale (FCCS-e) in adults with diabetes receiving primary care.
View abstractOBJECTIVE: To cross-culturally adapt the Foot Care Confidence Scale (FCCS) into Spanish and evaluate its measurement properties in adults with type 1 or type 2 diabetes receiving primary care in Spain. METHODS: A two-phase methodological study was conducted. Phase 1 included translation and back-translation, content validity assessment by 10 experts, and pretesting in 30 participants. Phase 2 included 1026 participants recruited from 30 primary care centres. Structural validity was examined using semi-confirmatory exploratory item factor analysis and Rasch analysis. Internal consistency and construct validity through hypothesis testing were also evaluated. RESULTS: Overall content validity was favourable (S-CVI/Ave = 0.908), although item 6 showed suboptimal item-level content validity. Factor analysis supported an essentially unidimensional structure (UniCo = 0.994; ECV = 0.910; MIREAL = 0.222), with high internal consistency (ordinal ω = 0.939; α = 0.899). Rasch analysis showed acceptable item fit and local independence, but disordered response-category thresholds and less precise targeting at higher levels of self-efficacy. Of 108 DIF comparisons, 101 (93.5%) were negligible. All four construct-validity hypotheses yielded results in the expected direction. CONCLUSION: The FCCS-e showed favourable evidence supporting content validity, structural validity, internal consistency, and construct validity based on hypothesis testing. Further studies should evaluate test-retest reliability, measurement error, responsiveness, and provide additional evidence of construct validity in independent populations and settings. |
Journal of tissue viability | 2026 Oct 29 | PubMed |
| 16 |
Immune checkpoint inhibitor-induced diabetes mellitus: A review of mechanisms, clinical features, and therapeutic approaches.
View abstractSince the FDA approval of ipilimumab in 2011, immune checkpoint inhibitors (ICIs) have reshaped the paradigm of cancer treatments. This has been pursued with the development and clinical investigation of combination immunotherapies with multiple ICIs. However, more than 20% of recipients of ICI monotherapy and a higher proportion of those who receive combination immunotherapy experience high-grade immune-related adverse events (irAEs). Checkpoint inhibitor-induced diabetes mellitus (CPI-DM) is a rare endocrine irAE, with an incidence rate of 0.2-3.5%, manifesting similarly to T1DM in most cases. Unlike other endocrine irAEs, CPI-DM is generally unresponsive to steroids and requires lifelong insulin treatment, hence exerting considerable morbidity on affected patients. The disruption of PD-1/PD-L1-mediated peripheral tolerance, the emergence of autoantibodies, INF-γ-driven inflammation, and cytotoxic T-cell- and pro-inflammatory monocyte/macrophage-mediated tissue destruction, under the shadow of genetic susceptibilities, are proposed to be central to CPI-DM pathogenesis. However, the pathogenic mechanisms and the management strategies of irAEs remain incompletely understood, and this review aims to summarize molecular and cellular events that underpin the development of CPI-DM, as well as its clinical presentations and novel, cell- and molecule-based preventive and therapeutic strategies. |
Pathology, research and practice | 2026 Oct 30 | PubMed |
| 17 | 'Mindshifting' type 1 diabetes care: Preparing UK services for the era of disease-modifying therapy. | Diabetic medicine : a journal of the British Diabetic Association | 2026 Oct 31 | PubMed |
| 18 |
Insulin Sensitivity and Insulin Secretion Differentially Affect Birthweight and Postpartum Glucose.
View abstractINTRODUCTION/OBJECTIVE: We tested whether early pregnancy insulin resistance and insulin deficiency are associated with infant birthweight percentile and postpartum glucose in women with diabetes risk factors. METHODS: This was a secondary analysis of data from the prospective Study of Pregnancy Regulation of Insulin and Glucose (SPRING). Participants were enrolled at 7-14 weeks' gestation and underwent a 2-hour oral glucose tolerance test (OGTT) with hourly glucose and insulin measures. Exposures were first-trimester (7-14 weeks' gestation) log-transformed insulin resistance and insulin secretory response, determined using the Matsuda index and Stumvoll first-phase estimate. Primary outcomes were birthweight percentile and 2-hour OGTT glucose at 6-24 weeks postpartum. Secondary outcomes included fasting, 30-min, and 1-hour OGTT glucose postpartum. We used covariate-adjusted linear regression models to quantify associations between standardized exposures and outcomes. RESULTS: Among 150 participants, greater first-trimester insulin resistance was associated with higher birthweight percentile (adjusted β: 5.11%, 95% CI: 0.04, 10.18 per 1 SD decrease in log Matsuda index), but not with postpartum glucose. Lower first-trimester insulin secretory response was not associated with birthweight percentile, but it was associated with higher postpartum 2-hour OGTT glucose (adjusted β: 13.96 mg/dL, 95% CI: 7.24, 20.69 per 1 SD decrease in log Stumvoll estimate), as well as glucose at the fasting, 30-min, and 1-hour post-OGTT time points postpartum. CONCLUSIONS: Insulin resistance and insulin deficiency in the first trimester are differentially associated with maternal and fetal outcomes. Assessing the underlying mechanisms of hyperglycemia in pregnancy may enable more personalized risk assessment. |
The Journal of clinical endocrinology and metabolism | 2026 Oct 31 | PubMed |
| 19 |
Impact of gestational diabetes mellitus and assisted reproductive technology on maternal and neonatal outcomes in twin pregnancies: A multicentre retrospective study in China.
View abstractAIMS: Twin pregnancies are inherently at high risk of maternal and neonatal complications. Assisted reproductive technology (ART) and gestational diabetes mellitus (GDM) are both common in this population, but it remains unclear whether their coexistence is associated with excess risk beyond their individual associations. METHODS: In this multicentre retrospective cohort of 4522 liveborn twin pregnancies across three hospitals in China, pregnancies were categorized according to mode of conception and GDM status. Generalized linear mixed models were used to estimate adjusted odds ratios (aORs) and 95% confidence intervals (CIs), with hospital included as a random effect. Multiplicative and additive interaction analyses were performed to assess whether the joint associations of ART and GDM with maternal and neonatal outcomes exceeded their individual associations. RESULTS: The overall prevalence of GDM was 22.2%, with 30.0% in ART-conceived women and 14.0% in spontaneously conceived (SC) women. Compared to SC twin pregnancies without GDM, ART-conceived twin pregnancies with GDM showed significantly increased risks of placental adhesion (aOR: 1.55; 95% CI: 1.03-2.33), caesarean section (aOR: 2.72; 95% CI: 1.21-6.15), preterm birth <37 weeks (aOR: 1.43; 95% CI: 1.15-1.78) and low birth weight (aOR: 1.27; 95% CI: 1.01-1.60). Notably, statistically significant multiplicative (aOR: 1.76; 95% CI: 1.11-2.80) and additive (relative excess risk due to interaction: 0.55; 95% CI: 0.14-0.96) interactions between GDM and ART were observed for preterm birth <34 weeks, whereas no statistically significant interactions were detected for the other examined outcomes. CONCLUSION: Twin pregnancies with both ART conception and GDM had higher risks of several adverse outcomes than spontaneously conceived pregnancies without GDM. However, evidence of statistical interaction between ART and GDM was limited to preterm birth <34 weeks, suggesting that the excess risk associated with their coexistence may be outcome-specific. These findings may help refine risk stratification and prenatal surveillance in twin pregnancies. |
Diabetic medicine : a journal of the British Diabetic Association | 2026 Oct 31 | PubMed |
| 20 |
Implementation and Phase 1 evaluation outcomes of the NHS England National Diabetes Transition and Young Adult Pilot Programme (2022-2026).
View abstractAIMS: This programme was a 4-year, centrally commissioned endeavour to gather evidence of strategies to implement a model service specification in 15 pilot sites and improve outcomes in 16- to 25-year-olds with diabetes. METHODS: Retrospective cohort study evaluating the quantitative and qualitative impact of implementing the model service specification on the study population. Phase 1 focused on changes and outcomes between 2022 and 2024. RESULTS: Services implemented changes to improve engagement, well-being, care process measurements and clinical outcomes. 6564 individuals' data were analysed across sites. At the end of 2024, caseloads increased by 15% for type 1 diabetes (T1D) and 64% for type 2 diabetes (T2D). Young adult multidisciplinary team appointments offered (2022: 5168, 2024: 9013) and attended (67.5% in 2024 vs. 64.1% in 2022, p < 0.001) surged, and non-attendance rates reduced (20.2% vs. 27.8%, p < 0.001). Measurements of HbA1c (73.2% vs. 69%, p < 0.01), blood pressure (69.1% vs. 57%, p < 0.0001), BMI (67.8% vs. 57%, p < 0.0001), psychological screening (43.8% vs. 14.7%, p < 0.0001) and uptake of hybrid closed loop systems increased. Median HbA1c reduced for the entire cohort (3 mmol/mol or 0.3%, p < 0.0001 for T1D, 4 mmol/mol or 0.4%, p = 0.2 for T2D). Treatment target achievement for HbA1c (T1D: 39.1%, p < 0.0001, T2D: 52.8%, p = 0.2) and blood pressure (T1D: 84.6%, p < 0.01, T2D: 74.1%, p = 0.3) increased. DKA admission rate (13.8 vs. 16.4, p < 0.05), hospital bed-days (42.1 to 30.1, p < 0.0001) and length of stay (2.57 to 2.18) reduced, with financial savings of £10,000/100 young people. Improved well-being was also reported. CONCLUSION: Early evaluation of the programme has shown improved outcomes for young people. |
Diabetic medicine : a journal of the British Diabetic Association | 2026 Oct 31 | PubMed |
| 21 |
The evolving burden of type 2 diabetes mellitus in Asia, 1990-2023: A Global Burden of Disease Study 2023.
View abstractAIMS: Asia accounts for over half of the global prevalence of type 2 diabetes mellitus (T2DM), yet subregional evidence remains limited. We assessed trends, regional disparities and risk-attributable burdens across Asia from 1990 to 2023. METHODS: We analysed the burden of T2DM across 34 countries and five regions across Asia, including Central, East, South and Southeast Asia and the high-income Asia Pacific region, using the Global Burden of Disease Study (GBD) 2023 from 1990 to 2023. T2DM was defined as a metabolic disorder characterised by insulin resistance and persistent hyperglycemia and was identified using ICD-10 codes E11-E11.1 and E11.3-E11.9. Age-standardised prevalence rate (ASPR) and disability-adjusted life year (DALY) rate (ASDR) with 95% uncertainty intervals (UIs) per 100,000 population were evaluated, and total percent changes (TPC) over the study period were calculated. Analyses were stratified by age group, sex and Socio-demographic Index (SDI). Additionally, we assessed the burden attributable to established risk factors for T2DM. RESULTS: ASPRs and ASDRs of T2DM increased across most Asian regions, with the largest increase exhibited in South Asia (ASPR TPC, 66.53 [95% UI, 61.77 to 71.77]; ASDR TPC, 75.59 [35.99 to 123.99] per 100,000 population). In contrast, High-income Asia Pacific showed a declining trend of ASDR (TPC, -2.42 [95% UI, -8.55 to 3.95]) per 100,000 population in 2023. Age-specific incidence rates generally peaked at 55-59 years in most Asian regions; however, East Asian males showed a distinct early peak at 20-24 years (509.61 [95% UI, 399.38 to 615.84] per 100,000 population). Particulate matter pollution was the leading attributable risk factor in all Asian regions. However, a diet low in fruits was the leading contributor in South Asia (157.12 [95% UI, 27.26 to 277.06] per 100,000 population), whereas processed meat consumption increased across most Asian regions, particularly in Central Asia. In most Asian countries, ASPRs increased with SDI, whereas ASDRs declined, although several South Asian countries showed disproportionately high prevalence for their SDI levels. CONCLUSIONS: Our findings provide updated regional insights into the heterogeneous epidemiology of T2DM in Asia and may inform targeted prevention and control strategies. |
Diabetic medicine : a journal of the British Diabetic Association | 2026 Oct 31 | PubMed |
| 22 |
Intervening in Adipocyte Senescence: Lipid Prodrugs as an Emerging Strategy for Metabolic Disease Treatment.
View abstractThe accelerating aging of the global population has made aging and its related diseases major public health challenges in the 21st century. Adipose tissue is not only an energy reservoir but also a crucial endocrine organ and metabolic regulator. Its dysfunction is closely linked to aging and the development of multiple diseases. This review outlines the key characteristics of adipocyte senescence and discusses its pathological contributions to obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, and cardiovascular diseases. It also summarizes current intervention strategies for adipocyte senescence, including senolytics, senomorphics, caloric restriction, physical exercise, and gene editing. We propose lipid prodrugs as promising adipose tissue delivery platforms that can be coupled with diverse therapeutic agents to increase the local concentration of drugs and minimize systemic toxicity. By utilizing the unique lipid metabolism of adipocytes, this strategy offers a new avenue for therapeutic intervention in adipocyte senescence and its associated metabolic disorders. |
Current medical science | 2026 Oct 29 | PubMed |
| 23 |
Single-cell transcriptomic analysis reveals fibroblast state-specific remodeling of purinergic signaling in diabetic gingiva.
View abstractDiabetes mellitus increases the risk and severity of periodontitis by disrupting periodontal mucosa homeostasis and promoting sustained chronic inflammation. Gingival fibroblasts are central regulators of periodontal integrity through extracellular matrix remodeling, immune modulation, and tissue repair. Purinergic signaling is an evolutionarily conserved pathway that regulates cellular metabolism and inflammatory responses, yet its role across distinct gingival fibroblast states in diabetes remains poorly understood. To address this gap, a publicly available single-cell RNA sequencing (scRNA-seq) dataset from wild-type (WT) and diabetic db/db mouse gingival tissue was analyzed. Fibroblasts were reclustered to identify transcriptionally distinct states, and genes associated with extracellular nucleotide signaling, adenosine signaling, ATP release, and inflammasome-associated pathways, including those related to Nlrp3 inflammasome. Genes were evaluated using differential expression, dot plots, UMAP feature plots, and state-specific log fold-change analyses. Four transcriptionally distinct fibroblast states were identified. Diabetic gingiva exhibited an expansion of the inflammatory fibroblast state accompanied by a reduction in ECM remodeling fibroblasts. Genes associated with extracellular nucleotide metabolism and adenosine signaling showed fibroblast state-specific expression patterns, including diabetes-associated differences in Nt5e (CD73), Entpd1 (CD39), and Enpp1 expressions. The adenosine receptor genes Adora2a and Adora2b were expressed at comparatively low levels. Genes associated with ATP release, including connexin-43 (Gja1) and pannexin-1 channels (Panx1), also displayed distinct state-specific expression patterns. Canonical inflammasome-associated genes were generally expressed at low levels, with Nek7 showing the highest overall expression and Casp11 exhibiting state-specific differences in expression, including a higher expression in selected diabetic fibroblast states. These findings identify an expansion of inflammatory fibroblasts in diabetic gingiva and characterize diabetes-associated changes in the expression of genes involved in extracellular nucleotide and nucleoside signaling, ATP release, and inflammasome-associated pathways that vary across fibroblast states. |
Purinergic signalling | 2026 Oct 31 | PubMed |
| 24 |
Glycemic control and weight loss benefits of fixed-ratio combinations of basal insulins and GLP1 receptor agonists in type 2 diabetes: A systematic review and network meta-analysis.
View abstractPURPOSE: To compare glycemic and weight effects of fixed-ratio combinations (FRCs) of basal insulin (BI) and glucagon-like peptide-1 receptor agonists (GLP1RAs) in adults with type 2 diabetes (T2D). METHODS: Randomized controlled trials of BI-GLP1RA FRCs in adults with T2D were identified across major databases through 20 December 2025. Co-primary outcomes were changes in glycated hemoglobin (HbA1c) and body weight. A frequentist random-effects network meta-analysis, with BI as the reference, was conducted in R using netmeta. Certainty was assessed using Confidence in Network Meta-Analysis (CINeMA). RESULTS: Thirty trials involving 17,862 participants were included. All FRCs reduced HbA1c and body weight more than BI alone. For HbA1c, HR17031 had the largest estimated reduction (mean difference [MD]: -0.72%), followed by IDegLira (-0.64%) and iGlarLixi (-0.53%). For body weight, IcoSema had the largest estimated reduction (-3.16 kg), followed by HR17031 (-1.74 kg) and IDegLira (-1.65 kg). No HR17031 comparison with other FRCs was statistically significant for either co-primary outcome; its ranking is hypothesis-generating. Excluding the high-risk-of-bias trial produced broadly consistent estimates. Compared with BI, FRCs increased achievement of HbA1c < 7%, often without weight gain or clinically significant/severe hypoglycemia. CINeMA indicated predominantly low- to moderate-certainty evidence for FRC versus BI comparisons and low- to very low-certainty evidence for many indirect comparisons among active regimens. CONCLUSIONS: BI-GLP1RA FRCs improve glycemic control and weight outcomes compared with BI alone. Rankings and apparent differences among FRCs or versus other active regimens warrant cautious interpretation given heterogeneity, inconsistency, and limited certainty of indirect evidence. |
Endocrine | 2026 Oct 31 | PubMed |
| 25 |
Dietary Pattern Modeling Reveals Gaps in Meal Kits in Meeting Nutritional Goals of Gestational Diabetes.
View abstractOBJECTIVE: To test whether a selection of commercial meal kits meets pregnancy and gestational diabetes mellitus (GDM) nutrient goals using a dietary pattern modeling approach. METHODS: Cross-sectional modeling of 64 theoretical daily patterns was performed using 12 randomly selected recipes (4 breakfasts, 4 lunches, and 4 dinners) drawn from a database of 1,220 recipes across 10 US commercial meal kit providers. Nutritional adequacy for pregnancy and GDM was assessed via Dietary Reference Intakes, and overall diet quality was assessed via the Healthy Eating Index 2020. RESULTS: Modeled intakes produced an average Healthy Eating Index score of 55.4 out of 100, indicating suboptimal diet quality. Fiber, vitamin D, iron, and calcium were consistently below the recommended levels. Carbohydrate content often exceeded GDM targets, and no recipes included whole grains. CONCLUSIONS AND IMPLICATIONS: Commercial meal kits did not meet pregnancy or GDM-specific nutrient goals. Dietary pattern modeling can identify gaps and guide the optimization of meal kits for future interventions. |
Journal of nutrition education and behavior | 2026 Oct 31 | PubMed |
| 26 | Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases | Nature Communications | 2026 | Scholar |
| 27 | Beyond Glycemic Control: Tirzepatide in a Woman With Prior Gestational Diabetes and High Cardiometabolic Risk | Journal of Gynecology Obstetrics and Mother Health | 2026 | Scholar |
| 28 | Sleep patterns, physical activity and glycemic control in newly diagnosed type 2 diabetes patients from a joint perspective: a cross-sectional study | Frontiers in Endocrinology | 2026 | Scholar |
| 29 | CLINICS OF METABOLIC AND MORPHOMETRIC FACTORS ASSOCIATED WITH THE REMISSION OF TYPE 2 DIABETES AFTER BARIATRIC INTERVENTIONS | Journal of modern medicine | 2026 | Scholar |
| 30 | Polyethylene Glycol Loxenatide Selectively Reduces Adiposity While Preserving Lean Body Mass in Type 2 Diabetes: A 12-Week Clinical Study | Diabetes, Metabolic Syndrome and Obesity | 2026 | Scholar |

